

Saskatchewan Immunization Manual Amendments - March 2026

Instructions: Discard the corresponding pages in each chapter section as noted below and insert **the amended pages** in the corresponding chapter sections.

Chapter 10 Biological Products

• TOC p. 1 and Content **Deletions**

- Avian influenza – Human H5N1 vaccine ARENPANRIX – No longer available
- DTaP-IPV-Hib – Pediacel – No longer available
- HB vaccine - PREHEVBRIO™ - No longer available
- **Publicly Funded Hepatitis A (HA) Vaccine Indications**
- First bullet now reads as, “People born since Jan. 1/82 who live: in the Athabasca Health Authority, off reserve in Northern SK (former Mamawetan Churchill River and Keewatin Yatthé health regions excluding Creighton, Air Ronge and La Ronge) or on reserve anywhere in SK, regardless of where they access immunization services.”

• 2025-26 COVID-19 Immunization Schedules (pages 1 and 2)

- **New** bullet added to page 1: Refer to the [Spring 2026 COVID-19 Booster Dose Eligibility](#) bulletin for eligibility criteria and interval information **effective April 1, 2026** ♦.
- ♦ added to Tables 2, 4 and 6 as reference to noted booster bulletin.

• MMRII and PRIORIX (pages 1 of 2)

- **New** indication #3: Susceptible immunocompromised individuals as referred by their specialist via submission of *Chapter 7, Immunization of Special Populations. Appendix 7.3: MMR Immunization Referral Form.*

• CAPVAXIVE® (Pneu-C-21)

- Immunosuppression related to disease or medical treatment clarified for transplant patient:
 - Immunosuppression related to disease or medical treatment (**for transplant patients - only HSCT recipients +65 years qualify, see footnote #2. SOT and Islet transplant patients are ineligible as per App. 7.9 & 7.10).**

• Pneu-C-21 Immunization Schedules for Individuals 65 Years and Older

- Immunosuppression related to disease or medical treatment clarified for transplant patient:
 - Immunosuppression related to disease or medical treatment (**for transplant patients - only HSCT recipients +65 years qualify, see footnote #4. SOT and Islet transplant patients are ineligible as per App. 7.9 & 7.10).**

• ABRYSVO RSV vaccine

- Product monograph hyperlink updated.
- Indications updated.

• mRESVIA RSV vaccine

- Indications updated.

• ROTARIX™

- This vaccine is not publicly funded in SK but administered in other provinces and territories.
- The primary series information is noted in table format.

• RotaTeq (Rot-5)

- Schedule is for infants 6 weeks through 32 weeks old.
- Footnote #1 now reads, “*Infants 6 weeks through 32 weeks old who have had rotavirus gastroenteritis before starting or completing the full RotaTeq® series should still initiate or complete the RotaTeq® series because the initial infection frequently provides only partial immunity.*”
- **New** statement added to footnote #6: “*Infants who received two ROTARIX™ doses on schedule DO NOT REQUIRE FURTHER RotaTeq doses.*”

• Product monograph hyperlinks updated.

IMVAMUNE VAXCHORA Vivotif RABAVERT HEPAGAM B VARIZIG HyperTET S/D
KAMRAB

Saskatchewan Immunization Manual Amendments - March 2026

Chapter 11 AEFIs

- **P. 1 Section 1.1.1 Publicly Funded Active Immunizing Agents**
 - First sentence now reads, “*Reportable AEFIs occurring after administration of Health Canada **approved** publicly funded active immunizing agents...*”
- **P. 2 Section 1.1.3 Other Pharmaceuticals**
 - **New** final sentence added: “*If a **vaccine was co-administered** with another health product (such as monoclonal antibodies), the report should be submitted to **both CAEFISS and CVP, using appropriate report forms.***”

Chapter 14 – Appendices

- All Ministry of Health letters removed.